Dr. Donohoe brings nearly 30 years of successful clinical and regulatory experience advancing medical devices in the cardiology and endovascular space NEW HOPE, Pa., Aug. 27, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical […]
Tag: Orchestra BioMed
Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships
Series B-1 Round Led by Perceptive, RTW and Soleus Capital with Strategic Participation from Terumo Corporation Secures $64 Million in 2019 Capital Inflows, Including $30 Million Upfront Payment from Terumo Partnership Financing Structure Provides Up to an Additional $57 Million […]
Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed’s Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership
TOKYO, June 13, 2019 /PRNewswire/ — Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced that it has secured exclusive global development and commercialization rights to Virtue® Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with […]
Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)
NEW HOPE, Pa., April 24, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet healthcare needs, announced today that it has secured Breakthrough Device designation by […]
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
NEW HOPE, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief […]
Orchestra BioMed™ to Present at the Piper Jaffray Healthcare Conference
NEW HOPE, Pa., Nov. 20, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced that David Hochman, Chairman and Chief Executive Officer, […]
Orchestra BioMed™ Announces Completion of $41 Million Financing
NEW HOPE, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced the successful final closing of a $41 million […]
Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)
NEW HOPE, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that Professor Petr Neuzil, M.D., Head of the […]
Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions
NEW HOPE, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has […]
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
NEW HOPE, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic Advisory Board […]